Homologous Recombination Deficiency Diagnostic Test

This opportunity seeks suppliers for an HRD (Homologous Recombination Deficiency) companion diagnostic test used in genomics to identify patients with homologous recombination deficiency among ovarian cancer populations. The test is a critical genomic tool that helps clinicians identify which ovarian cancer patients may benefit from targeted therapies. Suppliers should be prepared to demonstrate expertise in genomic testing, diagnostic accuracy, regulatory compliance (including FDA or equivalent approvals), quality assurance protocols, and the ability to process clinical samples at scale. The test supports precision medicine approaches in oncology and requires robust laboratory infrastructure and clinical validation.